secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001193125-24-018524
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose raises ~$13M in public offering and Hanmi PIPE for tuspetinib development
--------------------------------------------------------------------------------

- Underwriting agreement for 4,912,280 common shares and warrants at $1.71 per unit; net proceeds ~$9.0M.
- Over-allotment option fully exercised for additional 736,842 shares/warrants.
- Hanmi invests $4M for 2,105,263 common shares and 2,339,181 warrants at $1.90 per combined set.
- Hanmi will hold ~19.99% of outstanding shares post-offering; amended investor rights agreement.
- Proceeds from offering and PIPE to fund tuspetinib development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/d742545d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-018524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer